Avalo Therapeutics (AVTX) Q1 2026 Earnings
AVTX·Reported May 13, 2026·Before market open
Diluted EPS came in at $-0.98 (+21.6% YoY), beat the $-1.00 consensus by $0.02.
Diluted EPS
$-0.98beat by $0.02
Consensus: $-1.00
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Avalo Therapeutics's Q1 2026 earnings report.
Avalo Therapeutics (AVTX) reported Q1 2026 earnings on May 13, 2026 before market open.
Avalo Therapeutics reported diluted EPS of $-0.98 for Q1 2026.
EPS beat the consensus estimate of $-1.00 by $0.02.
Compared to the same quarter a year prior, diluted EPS grew 21.6% from $-1.25.
You can read the 8-K earnings release (0001534120-26-000032) and the 10-Q periodic report (0001534120-26-000033) directly on SEC EDGAR. The filing index links above go to sec.gov.